Menu
Novel therapeutics to conquer cancer:
Speeding smarter therapies to patients
UChicago researchers are advancing cancer treatment with new therapies that work with the
body’s healthy systems instead of against them, that leave patients stronger instead of weaker, that
destroy cancer and guard against its potential return.
Made in UChicago
A complete pipeline for new drug discovery―from basic research to chemical
synthesis, to designing delivery mechanisms, to preclinical testing, to clinical research―exists within the University of Chicago.
We are putting our deep scientific bench strength to work on producing new cellular therapies, advancing
theranostics―a one-two punch against cancer―that
simultaneously seeks out and destroys cancer cells without
damaging nearby tissue, and pursuing new ways to bolster
survivorship, such as preventing cachexia, the life-threatening wasting syndrome that many cancer patients develop.
A one-and-only scientific ecosystem
UChicago encompasses large-scale research enterprises engaged in cancer-relevant research. Each offers specialized skills and technologies not available elsewhere, allowing faster pursuit of deeper, more complex questions.
The Argonne National Laboratory >
The Duchossois Family Institute >
The Pritzker School for Molecular Engineering >
The Polsky Center for Entrepreneurship and Innovation >
The Argonne National Library
provides access to among the world’s
most powerful supercomputers and artificial intelligence to accelerate cancer
drug development.
The Duchossois Family Institute
research faculty are creating bacteria
products for next-generation probiotics as they explore the links between the
gut microbiome and successful response to cancer therapies.
The Pritzker School for Molecular Engineering
is the first school of its kind
where our faculty can design smarter, targeted, and more effective cancer
drugs.
The Polsky Center for Entrepreneurship and Innovation
combines experts
from the Booth School of Business with our physician-scientists to leverage
market potential and speed the delivery of new therapeutics to patients.
Our Comprehensive Cancer Center faculty offer clinical trials at twice the rate of their peers at other nationally recognized cancer
Masked cancer drug reduces
side-effects
Did you know? Developing a new
drug can take 10-15 years, from lab to patient, and require review of a quintillion (a billion billions) compounds.
Our Comprehensive Cancer Center faculty offer clinical trials at twice the rate of their peers at other nationally recognized cancer
Masked cancer drug reduces
side-effects
Did you know? Developing a new
drug can take 10-15 years, from lab to patient, and require review of a quintillion (a billion billions) compounds.
Our Comprehensive Cancer Center faculty offer clinical trials at twice the rate of their peers at other nationally recognized cancer centers.
NOVEL THERAPY
Mask cancer drug reduces side-effects
New immunotherapy would activate on contact with tumors.
